The financing round was led by Nasdaq Ventures, FactSet and IQ Capital, with support from existing investors.
"We are absolutely delighted to have secured USD 26 million in our Series B funding round. The investment is testament to the increasing need for more sophisticated tools to understand how markets truly behave and drive performance. Our granular Level 3 data and analytics capabilities help market participants unlock the full potential of the predictive power of historic pricing data and make more informed decisions."
The Oxford medical technology company secured backing from investors including Mercia and IQ Capital to scale its diagnostic software.
"Following years of research and clinical trials that have shown the impact of our software on the diagnosis of at-risk lung nodules, we’re focused on expanding patient access to this crucial technology and identifying deadly lung cancer faster in more at-risk people. The funding will also boost our research and development with world-leading institutions and partners to progress further innovation."
The seed round was led by IQ Capital with participation from several specialist energy and deep-tech investors.
"Working through a pandemic, scaling what was just an idea to fully functioning devices in less than three years, shows not only our team’s skill and dedication but the conviction of our network that IONATE is a key technology for the energy transition. With visionary experts from deep-tech venture capital, the utility sector, and academia in this round, we could not have chosen more strategic partners for achieving IONATE’s huge potential. I’m very excited for the next chapter and to work side-by-side with our investors and partners on what promises to be a time of extraordinary development and growth."
The Series B round was co-led by H.C. Starck Tungsten Powders and IQ Capital, valuing the business at £300m.
"We are excited to move our technologies from development to deployment in the market. We founded Nyobolt following the discovery of new anode technologies containing tungsten with remarkable fast charging capability to bring these properties to the market in applications touching all aspects of daily life. The funding from H.C. Starck will help Nyobolt to scale up our operations in the UK and United States and bring a more sustainable solution into the energy storage industry. Nyobolt technology will not only enable net zero both in the electrification of transport, but also the storing of clean and renewable energy on and off the grid. With the investment from H.C. Starck, Nyobolt’s ultra-fast charging, high power batteries will help lead the way towards achieving the clean energy goals set by governments around the world."
Susquehanna Growth Equity led the Series B round, which will fund international expansion and infrastructure upgrades.
"Our progress in the last few years left us inundated with interest from investors for our Series B fundraise. We chose to work with Susquehanna Growth Equity because they have a fantastic global footprint and a history of supporting significant growth in software businesses. The team is smart and ambitious but also pragmatic which is critical in this environment. The patient capital will enable us to double down on our vision to close the gap between humanity and machines, which is incredibly exciting. The Speechmatics team is hugely ambitious. We have a real heritage in speech technology combined with some of the world’s most talented speech and machine learning experts. We cannot wait to accelerate our growth and unlock the understanding of more and more voices."
